32 Results for "

Duocarmycin

" in MedChemExpress (MCE) Product Catalog:
Products (32)

32 Results for "Duocarmycin" in MCE Product Catalog:

Cat. No.: HY-164303
CAS No.: 1698870-53-9
Val-Cit-PAB-DEA-Duo-DM is a drug-linker conjugate, which consists of the linker Val-Cit-PAB, the spacer DEA and the ADC toxin Duocarmycin DM (Duo-DM) (HY-130978). Val-Cit-PAB-DEA-Duo-DM can be used for the synthesis of ADC molecule .
loading...
    loading...
Cat. No.: HY-160143
CAS No.: 2415664-00-3
Research Areas:  

Cancer

G3-VC-PAB-DMEA-Duocarmycin DM (Compound LD-1) is a duocarmycin-based linker molecule that can be used for ADC preparation ..
loading...
    loading...
Cat. No.: HY-171685
Anti-CCL2 (Carlumab)-MC-Vc-PAB-DMEA-PEG2-Duocarmycin SA is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated with the linker MC-Vc-PAB-DMEA-PEG2 and the DNA alkylator Duocarmycin SA (HY-12456). Anti-CCL2 (Carlumab)-MC-Vc-PAB-DMEA-PEG2-Duocarmycin SA can be used in cancer research .
loading...
    loading...
Cat. No.: HY-157465A
Purity:  99.05%
Research Areas:  

Cancer

MA-PEG4-VC-PAB-DMEA-duocarmycin DM TFA is a drug-linker conjugate for ADC by using the DNA minor-groove alkylator Duocarmycin DM (HY-130978), linked via MA-PEG4-vc-PAB-DMEA (HY-126668).
loading...
    loading...
Cat. No.: HY-19137
CAS No.: 154889-68-6
Synonyms: KW 2189 free base
Target:  

Antibiotic

Research Areas:  

Infection Cancer

Pibrozelesin (KW 2189 free base) is the derivative of antibiotic Duocarmycin B2. Pibrozelesin exhibits antitumor activity, inhibits proliferation of cell H69 with an IC50 of 1.9 μM. Pibrozelesin induces the DNA strand breaks upon activation via carboxyl esterase .
loading...
    loading...
Cat. No.: HY-107769R
CAS No.: 157922-77-5
Synonyms: CBI-TMI (Standard)
Duocarmycin TM (Standard) is the analytical standard of Duocarmycin TM (HY-107769). This product is intended for research and analytical applications. Duocarmycin TM (CBI-TMI) is a potent antitumor antibiotic. Duocarmycin TM induces a sequence-selective alkylation of duplex DNA.
loading...
    loading...
Cat. No.: HY-49559
CAS No.: 1049811-71-3
Target:  

Drug Intermediate

Research Areas:  

Cancer

Duocarmycin analog-3 (compound IV), the prodrug of carbamate, is an ADC synthesis intermediate. Duocarmycin analog-3 can be used in synthesis of ADCs .
loading...
    loading...
Cat. No.: HY-185153
Research Areas:  

Cancer

MC-VC-PAB-DMEA-PEG2-Duocarmycin SA is a drug-linker conjugate for ADC. MC-VC-PAB-DMEA-PEG2-Duocarmycin SA can be coupled with Carlumab (HY-P99188) to form Anti-CCL2 (Carlumab)-MC-Vc-PAB-DMEA-PEG2-Duocarmycin SA (HY-171685).
loading...
    loading...
Cat. No.: HY-160969
CAS No.: 1642147-15-6
Research Areas:  

Cancer

Spiro-duocarmycin is a DNA minor groove N3-adenine alkylating agent. Spiro-duocarmycin exerts cytotoxic effects via DNA alkylation. Spiro-duocarmycin is the active spirocyclized form of seco-DUBA, which is incorporated as an inactive prodrug into the linker-drug construct of antibody-drug conjugates (ADCs). DUBA serves as an ADC payload that can be conjugated with monoclonal antibodies to synthesize antibody-drug conjugates (ADCs) .
loading...
    loading...
Cat. No.: HY-164109
CAS No.: 494868-78-9
Target:  

Parasite

Research Areas:  

Infection Cancer

Tafuramycin A, a Duocarmycin derivative, is a potent anticancer and parasite attenuating agent. Tafuramycin A can be used for triple-negative breast cancer (TNBC) and malaria infection research .
loading...
    loading...
Cat. No.: HY-185488
CAS No.: 2592397-70-9
Research Areas:  

Cancer

seco-CBI dimer is a DNA alkylating agent and a prodrug of Duocarmycin, which can serve as a payload for synthesizing antibody-drug conjugates (ADCs). seco-CBI dimer binds to the minor groove of A-T-rich regions in DNA, alkylates the N3 position of adenine residues, and induces DNA strand breaks. seco-CBI dimer can be used in the research of non-Hodgkin's lymphoma .
loading...
    loading...
Cat. No.: HY-L023
116 compounds

Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.

The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 116 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.